Editas Medicine, Inc.

As of September 10, 2025, Editas Medicine, Inc. shows a mildly bullish technical trend with mixed signals from key indicators, having outperformed the S&P 500 in the short term but significantly underperformed over the past year.

As of March 30, 2016, Editas Medicine, Inc. is considered overvalued and risky due to its high Price to Book Value of 2.56 and low EV to EBITDA of 0.24, despite a strong ROCE of 142.55% and poor ROE of -317.44%, while its recent stock performance shows a significant year-to-date return of 136.22% but a 1-year decline of -22.68%, contrasting with the S&P 500's gains.

As of March 30, 2016, Editas Medicine, Inc. is considered a risky investment due to its overvaluation, highlighted by a price-to-book ratio of 2.56, a negative return on equity of -317.44%, and poor long-term performance despite a 65.35% year-to-date return.

As of June 5, 2025, the market trend is neutral with mixed indicators, showing mildly bullish momentum on weekly and monthly MACD, but daily moving averages and monthly KST are bearish, reflecting overall uncertainty in direction.

As of March 2022, the management team of Editas Medicine, Inc. includes Independent Chairman Mr. James Mullen, President and CEO Ms. Cynthia Collins, and several independent directors: Dr. Meeta Chatterjee, Mr. Andrew Hirsch, Dr. Jessica Hopfield, Dr. David Scadden, and Dr. Akshay Vaishnaw. This team provides governance and strategic direction for the company.

Editas Medicine, Inc. is a genome editing company focused on treating genetically defined diseases, with a market cap of $179.15 million and recent quarterly net sales of $5 million, but a net loss of $76 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

As of Jun 18, Editas Medicine, Inc. has a market capitalization of 179.15 million and reported net sales of 35.83 million, with a net profit loss of 251.24 million. Shareholder's funds are 134.27 million, and total assets amount to 341.59 million.